
---
title: 'JCM编辑荐读：新冠相关的血液系统疾病'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202207/08/114022iv50pv35wam59nu5.png'
author: 科学网
comments: false
date: Fri, 08 Jul 2022 11:58:00 GMT
thumbnail: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202207/08/114022iv50pv35wam59nu5.png'
---

<div>   
<p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">本期编辑荐读，精选了近两年发表在 <a href="https://www.mdpi.com/journal/jcm" target="_blank"><em>Journal of Clinical Medicine (JCM)</em></a> 的六篇文章，聚焦与新冠相关的血液疾病的预防、诊断与治疗。文章内容主要涉及用粘弹性测试预测血栓事件，新冠患者患血栓性微血管病、凝血功能障碍的预测及临床处理，新冠住院患者的输血要求等。希望能为相关领域学者提供新的思路和参考，欢迎阅读。</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";"><br></span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal; text-align: center;"><strong><span style="font-family: 微软雅黑, "Microsoft YaHei";">文章荐读</span></strong></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><strong><span style="font-family: 微软雅黑, "Microsoft YaHei";">1. Viscoelastometric Testing to Assess Hemostasis of COVID-19: A Systematic Review</span></strong></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">用于评估 COVID-19 止血的粘弹性测试；系统性综述</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">Marion Bareille et al.</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";"><a href="https://www.mdpi.com/2077-0383/10/8/1740" target="_blank">https://www.mdpi.com/2077-0383/10/8/1740</a></span></p><p style="text-align:center"><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202207/08/114022iv50pv35wam59nu5.png" title alt="7.png" referrerpolicy="no-referrer"></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal; text-align: center;"><span style="font-family: 微软雅黑, "Microsoft YaHei"; font-size: 14px;">图例：文献检索及选择方案。</span></p><p><span style="font-family: 微软雅黑, "Microsoft YaHei";">文章亮点：</span><br></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">(1) 该综述评估了粘弹性测试 (VET) 在预测 COVID-19 患者血栓事件方面潜在的临床用途，表征危重病 COVID-19 患者的止血异常。</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">(2) 研究了四种主要的商用VET设备(ROTEM、TEG、ClotPro 和 Quantra)的测试结果，该研究具有独创性。</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">(3) 具体讨论了COVID-19 患者纤维蛋白原的临床信息及抗凝方案，提出需要进一步的前瞻性研究来确定患者适合的抗凝方案。</span></p><p><br></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><strong><span style="font-family: 微软雅黑, "Microsoft YaHei";">2.  No Evidence for Classic Thrombotic Microangiopathy in COVID-19</span></strong></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">COVID-19中没有典型血栓性微血管病变的证据</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">Tanja Falter et al.</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";"><a href="https://www.mdpi.com/2077-0383/10/4/671" target="_blank">https://www.mdpi.com/2077-0383/10/4/671</a></span></p><p style="text-align:center"><br></p><p><br></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal; text-align: center;"><span style="font-family: 微软雅黑, "Microsoft YaHei"; font-size: 14px;">图例：COVID-19患者的止血参数。</span></p><p><span style="font-family: 微软雅黑, "Microsoft YaHei";">文章亮点：</span><br></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">(1) 该研究专注于弥散性血管内凝血 (DIC) 和经典血栓性微血管病 (TMA)的实验室特征和临床特征，来更多地了解 COVID-19 期间潜在的凝血病。</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">(2) 实验结果表明本研究中的患者不存在经典 TMA 的特征，需要进一步的病理生理学研究，以提供临床上有用的干预目标，改善病人的治疗效果。</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">(3) 与其他研究进行对比分析，文章通过 COVID-19 中主要的肺微血管病来解释缺乏 TMA 的实验室特征仍有待讨论。</span></p><p><br></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><strong><span style="font-family: 微软雅黑, "Microsoft YaHei";">3. Preventing Thrombohemorrhagic Complications of Heparinized COVID-19 Patients Using Adjunctive Thromboelastography: A Retrospective Study</span></strong></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">使用辅助血栓弹性成像预防肝素化 COVID-19 患者的血栓出血并发症：一项回顾性研究</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">Connor M. Bunch et al.</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";"><a href="https://www.mdpi.com/2077-0383/10/14/3097" target="_blank">https://www.mdpi.com/2077-0383/10/14/3097</a></span></p><p style="text-align:center"><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202207/08/114432vz4xxzalvxh9hz88.png" title alt="9.png" referrerpolicy="no-referrer"></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal; text-align: center;"><span style="font-family: 微软雅黑, "Microsoft YaHei"; font-size: 14px;">图例：COVID-19患者普通肝素给药方案。</span></p><p><span style="font-family: 微软雅黑, "Microsoft YaHei";">文章亮点：</span><br></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">(1) 证明了辅助血栓弹性成像 (TEG) 可能降低 ICU 患者的出血率，但并未降低血栓形成率。</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">(2) 表明 COVID-19 患者通过使用常规凝血测试和辅助血栓弹性成像来制定更安全、更有效的抗凝滴定策略。</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">(3) 分析证实了完全治疗性抗凝可能是有害的，其中病情较重、需要机械通气和 ECMO 的患者出血的风险很大。</span></p><p><br></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><strong><span style="font-family: 微软雅黑, "Microsoft YaHei";">4.  TEG®, Microclot and Platelet Mapping for Guiding Early Management of Severe COVID-19 Coagulopathy</span></strong></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">TEG®、微凝块生成试验和血小板图谱用于早期指导COVID-19重症凝血功能障碍的处理</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">Gert Jacobus Laubscher et al.</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">https://www.mdpi.com/2077-0383/10/22/5381</span></p><p style="text-align:center"><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202207/08/114605zzsieiqjbzsfw2we.png" title alt="10.png" referrerpolicy="no-referrer"></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal; text-align: center;"><span style="font-family: 微软雅黑, "Microsoft YaHei"; font-size: 14px;">图例：COVID-19的血管病理学。</span></p><p><span style="font-family: 微软雅黑, "Microsoft YaHei";">文章亮点：</span><br></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">(1) 文章综述了健康的可溶性纤维蛋白原与来自病毒和细菌的炎症因子结合后的凝结变化，分析 COVID-19 患者发生凝血障碍的病理学特征。</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">(2) 介绍了 TEG®、微凝块生成试验和血小板图谱的操作方法，及其如何对 COVID-19 患者的凝血临床参数进行早期密切监测。</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">(3) TEG® 参数、微凝块生成试验和血小板图能及时有效指导 COVID-19 的诊断与治疗，为解决 COVID-19 凝血障碍提供新的治疗方案和策略。</span></p><p><br></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><strong><span style="font-family: 微软雅黑, "Microsoft YaHei";">5. Mortality and Transfusion Requirements in COVID-19 Hospitalized Italian Patients According to Severity of the Disease</span></strong></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">意大利COVID-19住院患者依据疾病严重程度的死亡率和输血要求</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">Elvira Grandone et al.</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";"><a href="https://www.mdpi.com/2077-0383/10/2/242" target="_blank">https://www.mdpi.com/2077-0383/10/2/242</a></span></p><p style="text-align:center"><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202207/08/114630t15r1i89hrq9b7g8.png" title alt="11.png" referrerpolicy="no-referrer"></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal; text-align: center;"><span style="font-family: 微软雅黑, "Microsoft YaHei"; font-size: 14px;">图例：按输血需求和死亡率描述整个患者队列的图表。</span></p><p><span style="font-family: 微软雅黑, "Microsoft YaHei";">文章亮点：</span><br></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">(1) 文章分析了年龄、慢性肾脏病 (CKD) 和进入 ICU 的时间、输血需求是意大利 COVID-19 患者死亡率的主要预测要素。</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">(2) COVID-19 住院患者中，老年患者与 CKD 患者死亡率最高。COVID-19 住院患者的死亡率与合并症密切相关。</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">(3) COVID-19 进入 ICU 的住院患者对输血需求量相较于未进入 ICU 的住院患者的输血需求量更大，输血量越高，患者的死亡率越高。</span></p><p><br></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><strong><span style="font-family: 微软雅黑, "Microsoft YaHei";">6. Endothelial Activation and Stress Index (EASIX) as an Early Predictor for Mortality and Overall Survival in Hematological and Non-Hematological Patients with COVID-19: Multicenter Cohort Study</span></strong></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">内皮细胞激活和压力指数 (EASIX) 作为血液病和非血液病患者COVID-19的死亡率和总生存率的早期预测指标：多中心队列研究</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">Elżbieta Kalicińska et al.</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><a href="https://www.mdpi.com/2077-0383/10/19/4373" style="font-family: 微软雅黑, "Microsoft YaHei"; text-decoration: underline;" target="_blank"><span style="font-family: 微软雅黑, "Microsoft YaHei";">https://www.mdpi.com/2077-0383/10/19/4373</span></a> </p><p style="text-align:center"><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202207/08/114714yus8uu3lwpuclllw.png" title alt="12.png" referrerpolicy="no-referrer"></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal; text-align: center;"><span style="font-family: 微软雅黑, "Microsoft YaHei"; font-size: 14px;">图例：EASIX作为住院死亡率的预测指标。</span></p><p><span style="font-family: 微软雅黑, "Microsoft YaHei";">文章亮点：</span><br></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">(1) EASIX 可预测患有 COVID-19 的血液系统癌症和非血液系统癌症患者的临床结果和总生存期。EASIX 评分越高，COVID-19 患者的总生存期越低。</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">(2) EASIX 是 ICU 入院、住院死亡率和急性肾功能衰竭以及肾透析需求的主要预测因子。</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">(3) 诊断为 COVID-19 的血液系统癌症患者相比于未患有血液系统癌症患者具有更高的 EASIX，且感染后发生败血症的风险更高。</span></p><p><br></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">微信链接：<a href="https://mp.weixin.qq.com/s/sD0Y5mIuaDbS_pc_DTBKng" target="_blank">https://mp.weixin.qq.com/s/sD0Y5mIuaDbS_pc_DTBKng</a></span></p><p><br></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><a href="https://www.mdpi.com/journal/jcm" target="_blank"><strong><em><span style="font-family: 微软雅黑, "Microsoft YaHei";">JCM</span></em></strong></a><strong><span style="font-family: 微软雅黑, "Microsoft YaHei";"> 期刊介绍</span></strong></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">主编：Emmanuel Andrès, University Hospital of Strasbourg, France; Michael G. Hennerici, Ruprecht‐Karls‐Universität Heidelberg, Germany</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">期刊关注所有临床及临床前研究方面的论文，涵盖但不限于心脏病学、胃肠病学和肝胰胆病学、临床神经病学、肿瘤学、骨科、内分泌与代谢、肾脏科和泌尿科、流行病学与公共卫生、口腔科、肺病学、眼科、妇产科、免疫学、血液学、临床心理学与精神病学、耳鼻喉科、皮肤科、临床药理学等研究领域。</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">2021 Impact Factor 4.964</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">2021 CiteScore 4.4</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">Time to Publication 37.51 days</span></p><p style="margin-top: 5px; margin-bottom: 5px; line-height: normal;"><span style="font-family: 微软雅黑, "Microsoft YaHei";">Time to First Decision 20 days</span></p><p><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202207/08/115534eyw1ww5474f2122s.jpg" title alt="Picture16.jpg" referrerpolicy="no-referrer"><br></p><p><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202207/08/115608cmrmmnqwc40c0s3u.jpg" title alt="Picture5.jpg" referrerpolicy="no-referrer"><br></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自MDPI开放数字出版科学网博客。<br>链接地址：</label><a href="https://blog.sciencenet.cn/blog-3516770-1346394.html" target="_blank" style="font-size:13px; color:#850f0f">https://blog.sciencenet.cn/blog-3516770-1346394.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-3516770-1345938.html" target="_black">如何为您的研究论文挑选最好的标题？</a><br>下一篇：<a href="http://blog.sciencenet.cn/blog-3516770-1346399.html" target="_black">硼基路易斯酸催化的挑战与展望 | MDPI Catalysts</a>                    <!--大赛结束-->
                                        
  
</div>
            